August 1, 2016

Integra LifeSciences Announces that Omnigraft™ Dermal Regeneration Matrix was Recognized as a Top Ten Innovation by Podiatry Today

PLAINSBORO, N.J., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that its recently introduced product, Integra® Omnigraft™ Dermal Regeneration Matrix, has been recognized by Podiatry Today as one of the "Top Ten Innovations in Podiatry" in 2016.  Podiatry Today is an award-winning, premier publication that emphasizes informative clinical features and practice management articles.  Annually, Podiatry Today picks the most innovative products in the podiatric industry to showcase in their monthly publication.

In the article, Dr. Paul Kim, an Associate Professor and the Director of Research for the Department of Plastic Surgery at Georgetown, noted that Omnigraft was the subject of the largest multicenter randomized controlled trial to date on diabetic foot ulcers, with reported median time to complete DFU closure of 43 days in comparison to 78 days for patients treated with standard of care alone.  The full article is available at http://www.podiatrytoday.com/node.

Omnigraft was launched in May of 2016 and was featured at the American Podiatric Medical Association (APMA) 2016 Annual Scientific Meeting (The National) held in Philadelphia from July 14 — 17. APMA is a nationally recognized organization representing a majority of the estimated 15,000 podiatrists nationwide.  In addition to Omnigraft, Integra featured PriMatrix® Dermal Repair Matrix, PriMatrix® Ag Antimicrobial Dermal Repair Matrix and VolTAC™ Antimicrobial Wound Dressing. Collectively, Omnigraft, the PriMatrix product lines and VolTAC create a comprehensive portfolio of Smart Solutions for Serious Wounds™ within the outpatient setting.

About Omnigraft 
Omnigraft is the only FDA approved product that regenerates dermal tissue. It is an advanced bi-layer dermal regeneration matrix indicated for use in the treatment of partial and full-thickness neuropathic diabetic foot ulcers (DFUs) that are greater than six weeks in duration, with no capsule, tendon or bone exposed, when used in conjunction with standard diabetic ulcer care.

About Integra
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra.  Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results.  Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures.  In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Company

Investors
Angela Steinway
609-936-2268
angela.steinway@integralife.com

Michael Beaulieu
609-750-2827
michael.beaulieu@integralife.com

Media
Gianna Sabella
609-775-8553
gianna.sabella@integralife.com


Close window | Back to top

Copyright 2017 Integra LifeSciences Holdings Corporation